

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 October 2020 (08.10.2020)



(10) International Publication Number
WO 2020/205440 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 29/00 (2006.01)
C07K 16/28 (2006.01) A61P 35/02 (2006.01)
A61P 19/02 (2006.01)

(21) International Application Number:

PCT/US2020/025012

(22) International Filing Date:

26 March 2020 (26.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/826,660 29 March 2019 (29.03.2019) US
62/982,578 27 February 2020 (27.02.2020) US

(71) Applicant: **DREN BIO, INC.** [US/US]; 321 Grunion Ct.,
Foster City, California 94404 (US).

(72) Inventors: **TOMASEVIC, Nenad**; c/o Dren Bio, Inc., 321
Grunion Ct., Foster City, California 94404 (US). **SHI, Ruo**
Shi; c/o Dren Bio, Inc., 321 Grunion Ct., Foster City, Cali-
fornia 94404 (US). **KASHYAP, Arun**; c/o Dren Bio, Inc.,
321 Grunion Ct., Foster City, California 94404 (US).

(74) Agent: **JONES, Kevin**; Morrison & Foerster LLP, 425
Market Street, San Francisco, California 94105 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: METHODS OF REDUCING LARGE GRANULAR LYMPHOCYTE AND NATURAL KILLER CELL LEVELS




FIG. 4B

(57) Abstract: The present disclosure relates to methods of treating diseases or disorders associated with LGL and/or NK cells, methods of reducing or depleting LGL and/or NK cells, and methods of inducing ADCC activity using antibodies that bind to a cell surface protein on LGL and/or NK cells and comprise enhanced ADCC activity. The present invention also relates to a method of depleting or reducing the numbers of large granular lymphocytes and natural killer cells in a human subject upon administration of CD94 or CD57 or NKG2A binding molecule that consists of a part that specifically binds to the CD94 or CD57 or NKG2A receptors and an immunoglobulin Fc part. In a specific embodiment, a method of the invention depletes or reduces the number of large granular lymphocytes and natural killer cells in spleen, blood, bone marrow, joints, or other tissues.

[Continued on next page]

WO 2020/205440 A1

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))